Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 15 studies | 27% ± 8% | |
lung | 12 studies | 27% ± 10% | |
intestine | 7 studies | 24% ± 12% | |
brain | 6 studies | 25% ± 7% | |
kidney | 5 studies | 21% ± 3% | |
eye | 5 studies | 28% ± 12% | |
bone marrow | 4 studies | 25% ± 9% | |
lymph node | 4 studies | 22% ± 10% | |
liver | 3 studies | 34% ± 22% | |
breast | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5433.88 | 459 / 459 | 100% | 172.37 | 1118 / 1118 |
ovary | 100% | 4541.29 | 180 / 180 | 100% | 187.76 | 430 / 430 |
prostate | 100% | 4025.73 | 245 / 245 | 100% | 125.34 | 502 / 502 |
stomach | 100% | 3602.94 | 359 / 359 | 100% | 110.36 | 286 / 286 |
uterus | 100% | 4271.46 | 170 / 170 | 100% | 160.11 | 459 / 459 |
brain | 100% | 5856.41 | 2641 / 2642 | 100% | 138.62 | 705 / 705 |
esophagus | 100% | 3761.16 | 1444 / 1445 | 100% | 102.29 | 183 / 183 |
lung | 100% | 5295.76 | 578 / 578 | 100% | 152.62 | 1154 / 1155 |
thymus | 100% | 4917.10 | 653 / 653 | 100% | 119.65 | 604 / 605 |
skin | 100% | 5281.88 | 1809 / 1809 | 100% | 141.70 | 471 / 472 |
bladder | 100% | 4093.81 | 21 / 21 | 100% | 126.72 | 502 / 504 |
intestine | 100% | 4437.03 | 966 / 966 | 99% | 122.76 | 524 / 527 |
kidney | 100% | 4680.34 | 89 / 89 | 99% | 108.06 | 893 / 901 |
pancreas | 99% | 1856.49 | 325 / 328 | 99% | 119.48 | 177 / 178 |
liver | 100% | 2695.40 | 226 / 226 | 99% | 72.49 | 400 / 406 |
adrenal gland | 100% | 4684.23 | 258 / 258 | 97% | 93.81 | 223 / 230 |
adipose | 100% | 5456.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 130.98 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 136.76 | 29 / 29 |
muscle | 100% | 4938.07 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5010.89 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 175.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 65.83 | 1 / 1 |
blood vessel | 100% | 3757.97 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 3677.22 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 3126.28 | 888 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016925 | Biological process | protein sumoylation |
GO_1900180 | Biological process | regulation of protein localization to nucleus |
GO_0043392 | Biological process | negative regulation of DNA binding |
GO_0000776 | Cellular component | kinetochore |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0044389 | Molecular function | ubiquitin-like protein ligase binding |
GO_0031386 | Molecular function | protein tag activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SUMO3 |
Protein name | SMT3 suppressor of mif two 3 homolog 3 (Yeast), isoform CRA_d (Small ubiquitin like modifier 3) Small ubiquitin-related modifier 3 (SUMO-3) (SMT3 homolog 1) (SUMO-2) (Ubiquitin-like protein SMT3A) (Smt3A) Small ubiquitin like modifier 3 |
Synonyms | SMT3A SMT3H1 hCG_401304 |
Description | FUNCTION: Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4 . Plays a role in the regulation of sumoylation status of SETX . . |
Accessions | A8MU27 A8MUA9 ENST00000397893.3 P55854 ENST00000397898.7 ENST00000411651.6 [P55854-2] ENST00000332859.11 [P55854-1] |